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Aim: 
ROSIE is the first national, prospective, longitudinal, multi-
site drug treatment outcome study in the country. The NACD 
commissioned this research in 2002 as required by the National 
Drugs Strategy Action 99. The aim of the Study is to recruit and 
follow opiate users entering treatment over a period of time 
documenting the changes observed.
Method:
The study recruited 404 opiate users entering treatment and 
followed them over 3 years. Interviews were carried out at 
treatment intake, 6 months, 1-year and 3-years after treatment 
intake. Participants were recruited from methadone maintenance/
reduction (53.2%, n = 215), structured detoxification (20%, n = 81), 
abstinence-based treatment (20.3%, n = 82) and a sub-sample 
was recruited from needle exchange services (6.4%, n = 26). 
These modalities were considered to represent the most widely 
implemented interventions for opiate users in Ireland. Follow-up of 
participants was assisted by the provision of at least four contacts 
(locator information) for each person (including a drug treatment 
contact, family member, GP and others).
The main outcome measures in the study were drug using behaviour, 
physical and psychological health, harm, social functioning, 
mortality and crime.
ROSIE Baseline Findings
n	75% of participants were male
n	27 was the median (average) age of male participants
n	25 years was the median (average) age of female participants
n	86% of participants stated they were receiving the type of 
treatment they wanted
n	87% had engaged in some form of treatment prior to 
commencing their study intake treatment
n	The average (median) age at which participants first sought 
treatment was 20 years
n	On average participants first started smoking tobacco at 13 
years, drinking alcohol and smoking cannabis at age 14 years
n	On average participants first used heroin at 17 years
n	Respondents were less likely to consider their usage of other 
substances as problematic
n	More than three quarters of the participants reported recent 
use of two or more substances and 44% reported recent 
cocaine use. The Baseline findings showed dichotomous 
drinking patterns – 46% were non-drinkers and 42% heavy 
drinkers
n	The majority, 77%, had injected a drug and the average age  
of first injecting was 19 years (median)
n	17% of those who had injected did so before the age of 
17 years
n	63% of those who had ever injected used a needle after 
someone else, 63% shared filters and works and 88% reused 
their own injecting equipment
n	55% had never overdosed, the remainder had overdosed 
anywhere from once to five times or more
n	Just over half had seriously contemplated suicide
n	59% had left school by Junior Cert, the average age was 
15 years (mean and median)
n	33% had no qualifications
n	49% had Junior Cert/basic skills or NCVA Level 1
n	90% reported that they had ever committed a crime  
(excluding drug possession and traffic related offences)
n	55% had committed theft from a person
n	73% had committed theft from a commercial property and 48% 
had been arrested for this offence
n	76% had handled stolen goods and 27% had been arrested for 
this offence
n	70% had been involved with selling or supplying drugs and 31% 
had been arrested for this offence
n	All suffered from a range of physical and mental health problems, 
with 72% reporting poor appetite during the three months before 
interview. One quarter reported having thoughts of suicide in the 
six months prior to treatment intake, 10% attempted suicide in 
the six months prior to baseline interview and one third reported 
having attempted suicide in the past
n	Only 16% were employed (full-time or part-time) at baseline 
interview, while 21% had been employed over the previous three 
months. For 77% of participants their main source of income 
was social welfare.
Conclusions:
n	Polydrug use rates among ROSIE participants (76%) is 
consistent with those found in NTORS (81%) (UK National 
Treatment Outcome Research Study)
n	The analysis of ROSIE baseline data highlights that Irish drug 
treatment services are facing broadly the same challenges 
identified in many countries.
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ROSIE 2: Detoxification Modality 
Structured detoxification is a process whereby individuals are 
systematically and safely withdrawn from opiates, under medical 
supervision. The most common method of opiate detoxification 
in Ireland is to use methadone and slowly taper the dose down to 
zero over a period of time. Structured detoxification programmes 
are provided in both in-patient and out-patient facilities and can 
vary in duration from approximately 4-12 weeks.
Key Findings:
n	68% of participants successfully completed their intake 
detoxification treatment programme
n	(Illicit) drug abstinence rates (i.e. excluding alcohol) increased 
from 8% at treatment intake to 45% at 1-year
n	Abstinence from all drugs (including prescribed drugs) 
increased from 5% at treatment intake to 39% at 1-year
n	Participants’ use of heroin and other substances had reduced 
at 1-year
n	74% of participants reported no involvement in crime at 1-year 
compared to 19% at intake
n	Only 23% reported injecting at 1-year compared with 48% at 
intake
n	Improvements in physical and mental health symptoms were 
observed at 1-year
n	At 1-year follow up, 73% of participants were in some form of 
treatment; 42% were on prescribed methadone
n	The mortality rate for the cohort was 1.2% (1/81).
ROSIE 3: Abstinence Modality 
For the purposes of this study the abstinence modality is defined 
as being any structured programme which required individuals 
to be drug-free (including free from any pharmacological 
intervention) in order to participate in, and remain on, the 
programme. Such programmes provide intensive psychological 
support and a structured programme of daily activities which 
participants are required to attend. Treatment can occur in an 
inpatient (often referred to as residential rehabilitation) or an 
outpatient (i.e. structured drug-free day programmes) setting.
Key Findings:
n	66% completed their intake abstinence-based treatment 
programme
n	27% dropped out before programme completion
n	Abstinence from all drugs (including prescribed methadone  
and excluding alcohol) increased from 18% at treatment intake  
to 41% at 1-year
n	Cannabis was the only drug where no reductions in the 
numbers reporting use at treatment intake and 1-year were 
observed
n	The most substantial reductions over the follow-up period 
were in participants’ cocaine use, in terms of the proportions 
reporting use, the frequency of use and quantities consumed
n	Involvement in crime reduced across six of the 12 categories  
of offences
n	Improvements were observed in nine of the physical health 
symptoms, and five of the 10 mental health symptoms
n	The mortality rate of the cohort was 1.2% (1/82).
ROSIE 4: Methadone Modality 
The provision of methadone, a long-acting opiate agonist, 
under medical supervision, is the main pharmacological 
substitution intervention for opiate users in Ireland. Initially, a 
low commencing dose (usually between 10-40 mls) is prescribed, 
aimed at achieving a level of comfort while reducing the likelihood 
of overdose. By the end of six weeks of treatment, the individual is 
generally stabilized on an appropriate therapeutic dose.
Key Findings:
n	Retention in the methadone modality exceeded rates reported 
in comparable outcome studies
n	79% of the cohort were still receiving treatment in the 
methadone modality at 1-year follow-up
n	Reported use of heroin reduced from 84% at intake to 53% at 
1-year follow-up
n	The most substantial changes were in opiate consumption – 
use dropped from 50 days at intake to 15 at 1-year and 
quantity dropped from 1 gram to 0.3 grams at 1-year on a 
typical drug using day
n	Reductions in reported involvement in acquisitive crime (from 
28% at treatment intake to 15% at 1-year) and selling/supplying 
drugs (from 22% at treatment intake to 11% at 1-year) were 
observed
n	A decrease in the number of participants who reported 
injecting drug use and in the frequency of injecting drug use 
was observed at 1-year
n	Participants’ physical and mental health symptoms remained 
largely unchanged between treatment intake and 1-year  
follow-up
n	No participant had died in the 1-year follow-up period within 
this modality. 
